Moreover, we identified relevant signaling pathways (FAK, Wnt, Notch) and transcription factors (Egr1, TCF4), as constituents of this regulatory circuit, which paves the way for a more efficient combinatorial targeting of colon cancer in the context of therapeutic resistance. The gene discussed is PTK2; the disease is malignant colon neoplasm.